

# New therapeutic targets in stroke prevention: the effects of allopurinol on the cerebrovasculature of patients with subcortical stroke

<b>Submission date</b> 09/09/2005	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input type="checkbox"/> Protocol
<b>Registration date</b> 22/11/2005	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
<b>Last Edited</b> 01/02/2010	<b>Condition category</b> Circulatory System	<input type="checkbox"/> Individual participant data

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Matthew Walters

**Contact details**  
Department of Medicine & Therapeutics  
Western Infirmary  
44 Church Street  
Glasgow  
United Kingdom  
G11 6NT  
+44 (0)141 211 2821  
gcl203@clinmed.gla.ac.uk

## Additional identifiers

## Study information

Scientific Title

**Study objectives**

Treatment with xanthine oxydase inhibitor allopurinol will improve cerebrovascular reactivity in patients with subcortical stroke.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Not provided at time of registration

**Study design**

Randomised controlled trial

**Primary study design**

Interventional

**Study type(s)**

Treatment

**Health condition(s) or problem(s) studied**

Subcortical stroke.

**Interventions**

3 month allopurinol treatment (300 mg) versus lactose tablet.

**Intervention Type**

Drug

**Phase**

Not Specified

**Drug/device/biological/vaccine name(s)**

Allopurinol

**Primary outcome(s)**

The change in flow velocity in the middle cerebral artery (MCA) following acetazolomide infusion.

**Key secondary outcome(s)**

1. Change in serum urate
2. Recurrent stroke or other cardiac event

**Completion date**

01/11/2007

**Eligibility****Key inclusion criteria**

1. Subcortical stroke
2. Index stroke within 2 weeks and 3 months prior to randomisation

**Participant type(s)**

Patient

**Healthy volunteers allowed**

No

**Age group**

Adult

**Sex**

All

**Key exclusion criteria**

1. >70% Internal carotid artery stenosis
2. Coronary artery disease
3. Other significant comorbidity
4. Contraindication to allopurinol
5. Contraindication to acetazolamide
6. Concurrent azathioprine or 6-mercaptopurine therapy
7. Serum creatinine >250 µmol/l
8. Woman of childbearing potential

**Date of first enrolment**

01/11/2005

**Date of final enrolment**

01/11/2007

**Locations****Countries of recruitment**

United Kingdom

Scotland

**Study participating centre**

Department of Medicine & Therapeutics

Glasgow

United Kingdom

G11 6NT

**Sponsor information****Organisation**

Greater Glasgow NHS Board/Glasgow University (UK)

ROR

<https://ror.org/05kdz4d87>

## Funder(s)

**Funder type**

Charity

**Funder Name**

West Endowment Fund (UK)

## Results and Publications

Individual participant data (IPD) sharing plan

**IPD sharing plan summary**

Not provided at time of registration

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Results article</a>	results	01/11/2009		Yes	No